TICKERNERD
Menu
SGMTSGMTHealthcare · Biotechnology

SGMT Stock Forecast: Sagimet Biosciences, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$11
+13.69% on the day

The 9 Wall Street analysts covering Sagimet Biosciences, Inc. hold a median 12-month price target of $27 — +155.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 15 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$655.8M
Ticker Nerd rank
30 / 100
Median analyst target
$27
Analysts covering
9
Total return, dividends reinvested
1W
+16.4%
1M
+36.0%
YTD
+78.2%
1Y
+21.7%
From 52W high
0.0%
From 52W low
+131.9%
$5
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SGMT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sagimet Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
30 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
72
Momentum
70
Value
53
Quality
51
Size
51
Revisions
33
Accruals
22
Issuance
17
Volatility
16

Growth (72): Sales and profits are climbing, and climbing faster than before.

Volatility (16): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SGMT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SGMT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26SGMTHigh $49Median $27Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says9 analysts
8 Buy1 Hold0 Sell
Low $8Median $27High $49

The green dot is the last close — the median target sits +155.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
14 Aug 2026CitizensMaintainsMarket Outperform$12 → $29
12 Aug 2026Canaccord GenuityMaintainsBuy$49 → $56
19 May 2026CitizensMaintainsMarket Outperform$35 → $12
19 May 2026CitizensMaintainsMarket Outperform—
4 May 2026Canaccord GenuityMaintainsBuy—
29 Apr 2026GuggenheimMaintainsBuy—
11 Mar 2026HC Wainwright & Co.ReiteratesBuy—
3 Feb 2026GuggenheimInitiatesBuy—
3 Feb 2026HC Wainwright & Co.ReiteratesBuy—
28 Jan 2026BarclaysInitiatesEqual-Weight—
14 Nov 2025CitizensMaintainsMarket Outperform—
22 Oct 2025Clear StreetInitiatesBuy—
2 Oct 2025Canaccord GenuityMaintainsBuy—
11 Aug 2025WedbushInitiatesOutperform—
7 Aug 2025HC Wainwright & Co.AssumesBuy$29
24 July 2025Canaccord GenuityInitiatesBuy—
6 June 2025Jones TradingMaintainsBuy—
13 Mar 2025HC Wainwright & Co.ReiteratesBuy—
11 Mar 2025HC Wainwright & Co.ReiteratesBuy—
27 Jan 2025Jones TradingInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SGMT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SGMT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
1
Fundamentals

Sagimet Biosciences, Inc. (SGMT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.7×

Cheaper than 91% of US stocks

Price / sales
—
Price / book
3.4×

Cheaper than 32% of US stocks

EV / EBITDA
−6.0×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−24.4%

Higher than 29% of US stocks

Return on assets
−16.4%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SGMT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SGMTSagimet Biosciences, Inc.$655.8M
30
ASMBAssembly Biosciences, Inc.$653.0M
86
TECXTectonic Therapeutic, Inc.$653.4M
52
MDXGMiMedx Group, Inc.$634.4M
74
CBIOCrescent Biopharma, Inc.$633.5M
55
ZVRAZevra Therapeutics, Inc.$664.6M
97
FDMT4D Molecular Therapeutics, Inc.$621.8M
54

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sagimet Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SGMT news & analysis

Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data

MarketBeat · 17 Aug 2026positive

Sagimet Biosciences announced plans to initiate a U.S. Phase III study of its oral FASN inhibitor denifanstat for moderate-to-severe acne within the coming months, after its partner Ascletis reported positive results from a China-based Phase III trial. The disclosure was made by company executives during a Canaccord Genuity discussion.

Why it matters — The positive China Phase III results and planned U.S. Phase III study signal continued advancement of Sagimet's denifanstat pipeline into a new, potentially significant indication for acne.

Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

GlobeNewsWire · 13 Aug 2026positive

Sagimet Biosciences announced it received an FDA "Study May Proceed" letter and IND clearance for a Phase 3 clinical trial of denifanstat in moderate to severe acne in adolescent and adult patients in the U.S. The trial is on track to initiate in the second half of 2026.

Why it matters — This regulatory clearance advances Sagimet's acne program toward a Phase 3 trial, a key clinical milestone for the company's pipeline.

Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

GlobeNewsWire · 4 Aug 2026neutral

Sagimet Biosciences announced that its management will participate in the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, in Boston, MA, featuring a fireside chat.

Why it matters — The presentation provides an opportunity for Sagimet to discuss its pipeline with investors and industry analysts at a major growth conference.

FAQ

Frequently asked questions about SGMT stock

What is the SGMT stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Sagimet Biosciences, Inc. have a median 12-month price target of $27, with estimates ranging from $8 to $49. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SGMT stock a buy right now?

Of the 9 analysts covering Sagimet Biosciences, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sagimet Biosciences, Inc. 30 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SGMT?

As at 15 Aug 2026, Sagimet Biosciences, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (72 of 100).

Will SGMT stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +155.9% from the last close, and Ticker Nerd's factor model ranks Sagimet Biosciences, Inc. 30 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SGMT stock forecast for 2030?

No analyst covering Sagimet Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGMT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $49 over the next 12 months.

How has SGMT stock performed over the past year?

Sagimet Biosciences, Inc. returned +21.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sagimet Biosciences, Inc. do?

Sagimet Biosciences Inc. is a biotechnology company focused on the development of therapeutics targeting critical metabolic pathways in fibrotic diseases and cancer.

What is the latest news on SGMT?

The most recent item we track (MarketBeat, 17 Aug 2026): "Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data". Sagimet Biosciences announced plans to initiate a U.S. Phase III study of its oral FASN inhibitor denifanstat for moderate-to-severe acne within the coming months, after its partner Ascletis reported positive results from a China-based Phase III trial. The disclosure was made by company executives during a Canaccord Genuity discussion.

Company

About Sagimet Biosciences, Inc.

Sagimet Biosciences Inc. is a biotechnology company focused on the development of therapeutics targeting critical metabolic pathways in fibrotic diseases and cancer. The company's primary function is to leverage its proprietary platform to discover and develop small molecule drugs that can modulate key biological receptors implicated in disease progression. Sagimet's pipeline includes lead programs aimed at treating diseases such as nonalcoholic steatohepatitis (NASH) and certain forms of cancer, addressing significant unmet medical needs. By targeting specific metabolic enzymes, the company seeks to provide innovative treatment options that could potentially improve patient outcomes in these challenging and prevalent conditions. Sagimet Biosciences plays a crucial role in the healthcare and life sciences sectors, distinguishing itself with a focus on precision medicine and first-in-class therapeutics. This strategic approach positions the company as a significant player in the field of novel drug discovery and development within the broader pharmaceutical industry.

CEO Mr. David A. Happel · 16 employees · United States · https://www.sagimet.com